S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
3 Steel Stocks Could Soar on New China Tariffs
The “Perfect Storm” for Gold (Ad)
How major US stock indexes fared Thursday, 4/18/2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)
Bear Market Funds to Watch This Year
Shares of Walmart-backed Ibotta soar on public debut
Your Money is Not Safe (Ad)
Closing prices for crude oil, gold and other commodities
IMF's Georgieva says there's 'plenty to worry about' despite recovery for many economies
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
3 Steel Stocks Could Soar on New China Tariffs
The “Perfect Storm” for Gold (Ad)
How major US stock indexes fared Thursday, 4/18/2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)
Bear Market Funds to Watch This Year
Shares of Walmart-backed Ibotta soar on public debut
Your Money is Not Safe (Ad)
Closing prices for crude oil, gold and other commodities
IMF's Georgieva says there's 'plenty to worry about' despite recovery for many economies
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
3 Steel Stocks Could Soar on New China Tariffs
The “Perfect Storm” for Gold (Ad)
How major US stock indexes fared Thursday, 4/18/2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)
Bear Market Funds to Watch This Year
Shares of Walmart-backed Ibotta soar on public debut
Your Money is Not Safe (Ad)
Closing prices for crude oil, gold and other commodities
IMF's Georgieva says there's 'plenty to worry about' despite recovery for many economies
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
3 Steel Stocks Could Soar on New China Tariffs
The “Perfect Storm” for Gold (Ad)
How major US stock indexes fared Thursday, 4/18/2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)
Bear Market Funds to Watch This Year
Shares of Walmart-backed Ibotta soar on public debut
Your Money is Not Safe (Ad)
Closing prices for crude oil, gold and other commodities
IMF's Georgieva says there's 'plenty to worry about' despite recovery for many economies
Free Trial
OTCMKTS:ICOTF

iCo Therapeutics (ICOTF) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free ICOTF Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.39
▼
$0.39
50-Day Range
$0.30
▼
$0.42
52-Week Range
$0.80
▼
$1.82
Volume
1,000 shs
Average Volume
4,760 shs
Market Capitalization
$3.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
ICOTF stock logo

About iCo Therapeutics Stock (OTCMKTS:ICOTF)

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.

ICOTF Stock News Headlines

May 10, 2023 | wsj.com
ICO Group Ltd.
February 25, 2023 | marketwatch.com
Antisense & RNAi Therapeutics Market 2023 Estimated to Perceive Exponential Growth till 2028
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
February 19, 2023 | finance.yahoo.com
Women's health therapeutics market size to increase by USD 30.35 billion: North America to account for 37% of market growth - Technavio
February 19, 2023 | seekingalpha.com
Jasper Therapeutics releases promising early-stage data on sickle cell disease treatment
October 10, 2022 | usnews.com
Consumers to Ditch Cafes for Coffee at Home Amid Rising Prices, Says ICO
August 16, 2022 | investing.com
Satellos Bioscience Inc (MSCL)
June 1, 2022 | seekingalpha.com
Satellos Bioscience GAAP EPS of -C$0.06
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
December 16, 2021 | finance.yahoo.com
Satellos Bioscience Inc. Announces Scientific Research Agreement with Université de Sherbrooke to Study Rare Muscular Dystrophies
December 15, 2021 | finance.yahoo.com
Satellos Bioscience to Webcast Live at Life Sciences Investor Forum December 16th
December 9, 2021 | finance.yahoo.com
ICOTF: Targeting Stem Cells for Muscular Dystrophy Treatment
December 6, 2021 | finance.yahoo.com
Satellos Bioscience Announces New Board Appointments
December 2, 2021 | investing.com
iCo Therapeutics Inc (MSCL)
November 29, 2021 | finance.yahoo.com
Satellos Bioscience Reports Third Quarter 2021 Financial Results and Operational Highlights
October 27, 2021 | finance.yahoo.com
Satellos Bioscience Inc. Retains BND Projects Inc. for Strategic Investor Relations Services
August 5, 2021 | finance.yahoo.com
iCo Therapeutics Inc. Announces Shareholder Approval of Business Combination with Satellos Bioscience Inc.
See More Headlines
Receive ICOTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iCo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:ICOTF
CUSIP
N/A
CIK
N/A
Web
www.icotherapeutics.com
Phone
(905) 336-6128
Fax
604-602-9699
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.40)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-1,110,000.00
Net Margins
N/A
Pretax Margin
-4,148.78%
Return on Equity
N/A
Return on Assets
-288.85%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.72
Quick Ratio
0.72

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.07) per share
Price / Book
-5.57

Miscellaneous

Outstanding Shares
9,054,000
Free Float
N/A
Market Cap
$3.53 million
Optionable
Not Optionable
Beta
2.03
Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Frank Gleeson
    President & Chief Executive Officer
  • Warren Whitehead
    Chief Financial Officer
  • Michael Rudnicki
    Chief Scientific Officer
  • J. Robert Hall
    Vice President-Finance & Administration

Key Competitors

View All Competitors

This page (OTCMKTS:ICOTF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
The “Perfect Storm” for Gold
Gold Safe Exchange
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
Your Money is Not Safe
American Alternative